Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
65 hedge funds and large institutions have $281M invested in Ra Pharmaceuticals, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 9 reducing their positions, and 11 closing their positions.
278% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 9
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
8% more funds holding
Funds holding: 60 → 65 (+5)
5% less capital invested
Capital invested by funds: $297M → $281M (-$16.2M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.7M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$8.93M |
| 3 |
BlackRock
New York
|
+$6.23M |
| 4 |
Millennium Management
New York
|
+$3.42M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$2.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$7.79M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$4.85M |
| 3 |
Jennison Associates
New York
|
-$4.31M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$4.26M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$2.36M |
RARX Hedge Fund Activity: Q2 2017 in Review
65 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q2 2017, worth a combined $281M — down 5.5% from $297M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RARX positions and 11 closed out — a net gain of 5 holders — while 34 added to existing stakes and 9 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $10.7M. The largest seller was Franklin Resources, exiting entirely with an estimated $7.79M sold.
- 65 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q2 2017, up from 60 in Q1 2017.
- Funds reported $281M of Ra Pharmaceuticals, Inc. Common Stock stock for Q2 2017, down 5.5% quarter-over-quarter.
- 16 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q2 2017 and 11 closed out, a net change of +5 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q2 2017 was Wellington Management Group, an estimated $10.7M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q2 2017 was Franklin Resources, an estimated $7.79M sold.
Based on aggregated 13F filings for Q2 2017.